Sun Pharmaceutical Industries’s ophthalmic business in the US has received a boost, with the US Food and Drug Administration (USFDA) accepting the company’s application for a novel medicine to treat dry-eye disease.
Investors cheered the development and the company stock gained 6.89 per cent to close at Rs 577.70 on the BSE on Wednesday.
Sun Pharma is building its specialty drugs business in the US through acquisitions, increased spending on research and development, and dedicated sales teams.
Currently, the company markets four specialty drugs in the US, and overall the market contributed about 30 per cent to the company’s revenue